Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 25, 2015 (11 years ago)

Bromfenac Ophthalmic Solution 0.09%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Failed preservative effectiveness testing

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Bromfenac Ophthalmic Solution 0.09%, packaged in a) 1.7 mL bottle (NDC 60505-0595-05), b) 2.5 mL bottle (NDC 60505-0596-04), Rx Only, Mfg for: Apotex Corp., Weston, FL 33326.

Affected NDCs 60505-0595-05 60505-0596-04

Compare with the code on your package — it is the most precise check available.

Drug: Bromfenac Category: Eye Drops & Ophthalmic

Recalling firm
Apotex Inc.
NDC code
60505-0595-05
Origin
N/A, Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0009-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bromfenac recalls

See all
Class II · Moderate risk

Bromfenac Ophthalmic Solution 0.07%

Failed Impurities/Degradation Specifications: out of specification at the time of testing i.e. 20th month stability testing.

Ongoing Impurity / degradation Alembic Pharmaceuticals, INC. NDC 62332-583-03 Recall number pending

Other recalls by Apotex Inc.

All 2015 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026